Prestige Healthcare Reports Q2 2027 Revenue Growth Driven by Acquisitions Amid Eye Care Production Volatility
Prestige Healthcare (PBH) reported a significant increase in total revenue for the second quarter, reaching $336.3 million, a 22.7% year-over-year rise. This growth was primarily fueled by the first full quarter of contributions from the Breathe Right and LaCorium acquisitions. Despite this top-line strength, organic revenue declined by 1.6% due to production challenges and order timing issues affecting the Clear Eyes brand. In response to eye care supply variability and higher interest expenses from acquisition financing, management has lowered its full-year revenue guidance to a range of $1.28 billion to $1.29 billion. While adjusted diluted EPS rose to $1.13, the company is navigating production volatility that began in late September. Management remains focused on debt reduction, targeting a leverage ratio of approximately fourfold by fiscal year-end using strong free cash flow.
Topics: Acquisitions EBITDA Margin EPS Guidance Downgrade Revenue Growth